Literature DB >> 11903367

Clinical and pathological characteristics of oral lichen planus in hepatitis C-positive and -negative patients.

María Amparo Romero1, J Seoane, P Varela-Centelles, P Diz-Dios, X L Otero.   

Abstract

The reported prevalence rate of anti-hepatitis C virus (HCV) antibodies in patients with oral lichen planus shows wide geographical variation and ranges from 0 to 65%. Certain characteristic clinical features have been attributed to oral lichen planus associated to HCV infection. The purpose of this investigation has been to assess hypothetical clinical differences, as well as differences in the intensity of the subepithelial inflammatory infiltrate between oral lichen planus-HCV +ve patients and oral lichen planus-HCV -ve patients. A total of sixty-two patients entered the study. Their mean age was 63.5 +/- 14.49 years, and 48.4% of them were men and 51.6% women. Patients were classified according to their serum HCV positivity. Age, sex, clinical presentation (reticular or atrophic-erosive), extension of the lesions, location of the lesions, number of locations affected, intensity of the inflammatory infiltrate and Candida albicans colonization were recorded for each patient. Reticular lichen planus was the most frequent clinical presentation in both HCV +ve (57.1%) and HCV -ve patients (63.6%). C. albicans colonization ranged from 42.8% in HCV +ve and 41.7% in HCV -ve patients. HCV + ve patients showed certain oral locations more frequently affected than HCV -ve ones: lip mucosa, 28.6% versus 7.3%; tongue, 57.1% versus 29.1%; and gingiva, 71.4% versus 23.6%. The number of affected intraoral locations was higher in HCV +ve patients (71.4%) than among HCV -ve ones (20.4%; chi2 = 8.34; P < 0.011). No statistically significant differences could be established in terms of density of subepithelial inflammatory infiltrate between the groups. Our results reinforce the need for liver examination in all patients with oral lichen planus, particularly those showing lesions on the gingiva with multiple intraoral locations affected, as no pathological differences could be identified between HCV + ve and HCV -ve patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11903367     DOI: 10.1046/j.0307-7772.2001.00516.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  7 in total

1.  Oral Lichen Planus as an Extra-hepatic Manifestation of Viral Hepatitis-Evaluation in Indian Subpopulation.

Authors:  Mohan Kumar K P; Harshavardhan S Jois; Seema Hallikerimath; Alka D Kale
Journal:  J Clin Diagn Res       Date:  2013-07-19

2.  Possible link between Hashimoto's thyroiditis and oral lichen planus: a novel association found.

Authors:  Lorenzo Lo Muzio; Andrea Santarelli; Giuseppina Campisi; Mariagrazia Lacaita; Gianfranco Favia
Journal:  Clin Oral Investig       Date:  2012-06-15       Impact factor: 3.573

Review 3.  Oral manifestations of hepatitis C virus infection.

Authors:  Marco Carrozzo; Kara Scally
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

4.  Prevalence of hepatitis C and hepatitis B virus infection(s) in patients with oral lichen planus.

Authors:  Perumal Jayavelu; Thirumal Sambandan
Journal:  J Pharm Bioallied Sci       Date:  2012-08

5.  Lack of evidence of hepatitis in patients with oral lichen planus in China: A case control study.

Authors:  Jiangyuan Song; Zhihui Zhang; Xiaoli Ji; Sha Su; Xiaodan Liu; Si Xu; Ying Han; Dongdong Mu; Hongwei Liu
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2016-03-01

6.  Lack of Association between Oral Lichen Planus and Hepatitis B and C Virus Infection - a Report from Southeast Iran

Authors:  Tahereh Nosratzahi; Mehrab Raiesi; Bahareh Shahryari
Journal:  Asian Pac J Cancer Prev       Date:  2018-06-25

Review 7.  Oral lichen planus: clinical and histopathological considerations.

Authors:  Fernando Augusto Cervantes Garcia de Sousa; Luiz Eduardo Blumer Rosa
Journal:  Braz J Otorhinolaryngol       Date:  2008 Mar-Apr
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.